People · Operator
Named in public records as an officer, director or promoter · active 2009–2026 · Biotechnology, Healthtech, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ocugen, Inc. | — | Biotechnology | Series B | $145.6M | $566.9M | 2012 |
| TELA Bio, Inc. | — | Biotechnology | Series C | $104.8M | $435.1M | 2017 |
| Cheetah Medical, Inc. | — | Healthtech | Series B | $59.6M | $74.4M | 2017 |
| Aziyo Biologics, Inc. | — | Biotechnology | Series A | $54.6M | $80.2M | 2021 |
| Convexity Scientific Inc. | — | Other Health Care | Series B | $37.8M | $2.4M | 2019 |
| Helix Therapeutics, Inc. | — | Biotechnology | Seed | $2.8M | $111.0M | 2009 |
| CyOmics, LLC | — | Biotechnology | Pre-Seed | $700K | $38.6M | 2015 |
Kevin Rakin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Rakin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin McArdle | 2 | 3 |
| John Johnson | 1 | 25 |
| Garheng Kong | 1 | 16 |
| Christopher Smith | 1 | 15 |
| Michael Lewis | 1 | 12 |
| Adele Oliva | 1 | 9 |
| Timothy Shannon | 1 | 9 |
| Stephen Reeders | 1 | 9 |
| KEVIN CROWLEY | 1 | 9 |
| Stephen Bruso | 1 | 9 |
| F. Kevin Didden | 1 | 6 |
| Patrick O'Donnell | 1 | 6 |
| Matthew Ferguson | 1 | 6 |
| Adele C. Oliva | 1 | 5 |
| Per Hellsund | 1 | 4 |
| Adam Gridley | 1 | 4 |
| Richard Wilmot | 1 | 4 |
| Russell Tweeddale | 1 | 4 |
| Matt Zuga | 1 | 4 |
| Antony Koblish | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.